Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avalo Therapeutics, Inc. (AVTX)
USD18.64
+0.22 (+1.17%)
US NASDAQ Healthcare Biotechnology
Address
540 Gaither Road 20850
Rockville, MD, US
Rockville, MD, US
CEO
Garry A. Neil
Website
avalotx.com
IPO
2015-10-14
CIK 1534120 ISIN US05338F3064
Description
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Cerecor Inc. | CERC | 2019-12-20 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD18.64
+0.22 (+1.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.82
Float Shares
10.84M
Free Float %
96.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.53% | -10.58% | +45.97% | +38.47% | +29.23% | +9.80% | +398.50% | -96.62% | -99.71% | -99.82% | -99.89% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
18.64
Low
39.00
+109.3%
Consensus
51.00
+173.7%
Median
50.00
+168.3%
High
60.00
+222.0%
DCF (Unlevered)
0.99
-94.7%
DCF (Levered)
0.99
-94.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
59.00
+216.6%
|
| Last Quarter | 3 |
55.33
+196.9%
|
| Last Year | 6 |
46.67
+150.4%
|
| All Time | 8 |
42.25
+126.7%
|
Quality scores
Altman Z-Score
-2.72
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-86.6%
-
EPS growth Biotechnology: +29.7%-79.1% Q1'26: +21.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-117,371.2%
-
EBIT margin Biotechnology: +0.0%-123,601.7%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+24.3% Q1'26: +91.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 8 EPS Ana. |
Dec 2027 11 Rev. Ana. 7 EPS Ana. |
Dec 2028 7 Rev. Ana. 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.15M
est: 1.37M (-16.0%)
|
27.81M
est: 2.80M (+893.3%)
|
18.33M
est: 18.73M (-2.1%)
|
6.75M
est: 17.76M (-62.0%)
|
6.70M
est: 5.20M (+28.8%)
|
5.40M
est: 6.08M (-11.3%)
|
18.05M
est: 20.80M (-13.2%)
|
1.92M
est: 807.0K (+138.4%)
|
441.0K
est: 183.0K (+141.0%)
|
59.0K
est: 1.00M (-94.1%)
|
1.00M
1.00M – 1.00M
+0.0% YoY
|
1.00M
1.00M – 1.00M
+0.0% YoY
|
13.9K
13.9K – 13.9K
-98.6% YoY
|
11.05M
11.05M – 11.05M
+79,488.0% YoY
|
120.32M
120.32M – 120.32M
+988.9% YoY
|
| EBITDA |
-16.05M
est: -1.37M (-1,070.1%)
|
14.35M
est: -2.80M (+612.3%)
|
-13.07M
est: -18.73M (+30.2%)
|
-13.51M
est: -17.76M (+23.9%)
|
-45.45M
est: -5.20M (-774.1%)
|
-80.48M
est: -6.08M (-1,222.7%)
|
-37.27M
est: -20.80M (-79.2%)
|
-23.29M
est: -807.0K (-2,785.5%)
|
-68.34M
est: -183.0K (-37,245.9%)
|
-72.93M
est: -1.00M (-7,192.5%)
|
-1.00M
-1.00M – -1.00M
+0.0% YoY
|
-1.00M
-1.00M – -1.00M
+0.0% YoY
|
-13.9K
-13.9K – -13.9K
+98.6% YoY
|
-11.05M
-11.05M – -11.05M
-79,488.0% YoY
|
-120.32M
-120.32M – -120.32M
-988.9% YoY
|
| EBIT |
-16.08M
est: -1.37M (-1,072.0%)
|
13.89M
est: -2.80M (+596.1%)
|
-14.90M
est: -18.73M (+20.4%)
|
-17.39M
est: -17.76M (+2.1%)
|
-47.29M
est: -5.20M (-809.5%)
|
-82.13M
est: -6.08M (-1,250.0%)
|
-37.44M
est: -20.80M (-80.0%)
|
-23.44M
est: -807.0K (-2,805.1%)
|
-68.51M
est: -183.0K (-37,338.3%)
|
-72.93M
est: -1.00M (-7,192.5%)
|
-1.00M
-1.00M – -1.00M
+0.0% YoY
|
-1.00M
-1.00M – -1.00M
+0.0% YoY
|
-13.9K
-13.9K – -13.9K
+98.6% YoY
|
-11.05M
-11.05M – -11.05M
-79,488.0% YoY
|
-120.32M
-120.32M – -120.32M
-988.9% YoY
|
| Net Income |
-16.47M
est: -73.92B (+100.0%)
|
11.87M
est: -33.23B (+100.0%)
|
-40.05M
est: -27.49B (+99.9%)
|
-16.07M
est: -11.49B (+99.9%)
|
-63.50M
est: -24.54B (+99.7%)
|
-84.38M
est: -24.35B (+99.7%)
|
-41.66M
est: -7.53B (+99.4%)
|
-31.54M
est: -670.36M (+95.3%)
|
-35.13M
est: -46.22M (+24.0%)
|
-78.26M
est: -88.66M (+11.7%)
|
-46.59M
-61.51M – -31.67M
+47.4% YoY
|
-57.27M
-90.08M – -24.45M
-22.9% YoY
|
-51.70M
-80.34M – -23.05M
+9.7% YoY
|
-45.78M
-45.78M – -45.78M
+11.4% YoY
|
-24.35M
-24.35M – -24.35M
+46.8% YoY
|
| SGA |
7.08M
est: 14.57M (-51.4%)
|
8.91M
est: 29.74M (-70.0%)
|
19.20M
est: 198.92M (-90.3%)
|
11.61M
est: 188.65M (-93.8%)
|
19.76M
est: 55.24M (-64.2%)
|
24.66M
est: 64.63M (-61.8%)
|
20.71M
est: 220.91M (-90.6%)
|
10.30M
est: 70.74M (-85.4%)
|
17.24M
est: 16.04M (+7.5%)
|
22.90M
est: 87.66M (-73.9%)
|
87.66M
87.66M – 87.66M
+0.0% YoY
|
87.66M
87.66M – 87.66M
+0.0% YoY
|
1.22M
1.22M – 1.22M
-98.6% YoY
|
968.64M
968.64M – 968.64M
+79,488.0% YoY
|
10.55B
10.55B – 10.55B
+988.9% YoY
|
| EPS |
-21.93
est: -6,854.40 (+99.7%)
|
1,856.88
est: -3,081.60 (+160.3%)
|
-3,317.28
est: -2,548.80 (-30.2%)
|
-819.74
est: -1,065.60 (+23.1%)
|
-2,523.77
est: -2,275.20 (-10.9%)
|
-2,330.66
est: -2,257.92 (-3.2%)
|
-1,062.65
est: -698.40 (-52.2%)
|
-113.58
est: -50.01 (-127.1%)
|
-4.32
est: -18.45 (+76.6%)
|
-5.84
est: -6.71 (+13.0%)
|
-3.54
-4.59 – -2.36
+47.3% YoY
|
-4.03
-6.72 – -1.82
-14.0% YoY
|
-3.69
-5.99 – -1.72
+8.5% YoY
|
-3.42
-3.42 – -3.42
+7.5% YoY
|
-1.82
-1.82 – -1.82
+46.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-11 | Piper Sandler | Overweight | Overweight | Maintain |
| 2026-05-06 | Wedbush | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-51.72M
OE per share TTM
-4.21
Owner's Yield
-19.05%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
30.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
25.14M
Insider transactions (90d)
8
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 970.4K | 10.02% | — | 970.4K | — | 970.4K | IA | Delaware | 2024-10-07 | ↗ |
| 2 | Neil Shahrestani | 970.4K | 10.02% | — | 970.4K | — | — | HC, IN | Delaware | 2024-10-07 | ↗ |
| 3 | BVF Inc. | 967.3K | 9.99% | — | — | — | 967.3K | CO | Delaware | 2024-08-23 | ↗ |
| 4 | BVF Partners L.P. | 967.3K | 9.99% | — | — | — | 967.3K | IA, PN | Delaware | 2024-08-23 | ↗ |
| 5 | Mark N. Lampert | 967.3K | 9.99% | — | — | — | 967.3K | IN | Delaware | 2024-08-23 | ↗ |
| 6 | s | 967.3K | 9.99% | — | 967.3K | — | — | PN | Delaware | 2024-08-23 | ↗ |
| 7 | OrbiMed Advisors LLC | 967.0K | 9.90% | — | 967.0K | — | — | IA | Delaware | 2024-11-14 | ↗ |
| 8 | BVF GP Holdings LLC | 915.5K | 9.50% | — | — | — | 915.5K | OO | Delaware | 2024-08-23 | ↗ |
| 9 | OrbiMed Capital GP IX LLC | 644.7K | 6.70% | — | 644.7K | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 10 | BVF I GP LLC | 512.3K | 5.30% | — | — | — | 512.3K | OO | Delaware | 2024-08-23 | ↗ |
| 11 | Biotechnology Value Fund, L.P. | 512.3K | 5.30% | — | — | — | 512.3K | PN | Delaware | 2024-08-23 | ↗ |
| 12 | BVF II GP LLC | 403.1K | 4.20% | — | — | — | 403.1K | OO | Delaware | 2024-08-23 | ↗ |
| 13 | Biotechnology Value Fund II, L.P. | 403.1K | 4.20% | — | — | — | 403.1K | PN | Delaware | 2024-08-23 | ↗ |
| 14 | J. Crutcher | 110.9K | 9.90% | 110.9K | — | 110.9K | — | IA | USA | 2024-08-23 | ↗ |
| 15 | Allostery Investments GP LLC | 78.3K | 7.60% | — | 78.3K | — | 78.3K | OO | Cayman Islands | 2024-05-13 | ↗ |
| 16 | Allostery Investments LP | 78.3K | 7.60% | — | 78.3K | — | 78.3K | PN | Cayman Islands | 2024-05-13 | ↗ |
| 17 | Allostery Master Fund LP | 78.3K | 7.60% | — | 78.3K | — | 78.3K | PN | Cayman Islands | 2024-05-13 | ↗ |
| 18 | Christopher Staral | 78.3K | 7.60% | — | 78.3K | — | 78.3K | IN | Cayman Islands | 2024-05-13 | ↗ |
| 19 | David Modest | 78.3K | 7.60% | — | 78.3K | — | 78.3K | IN | Cayman Islands | 2024-05-13 | ↗ |
| 20 | Timothy Opler | 58.3K | 5.60% | — | 58.3K | — | 58.3K | IN | Delaware | 2024-04-23 | ↗ |
| 21 | BVF Partners OS Ltd. | 37.8K | 1.00% | — | — | — | 37.8K | CO | Delaware | 2024-08-23 | ↗ |
| 22 | Biotechnology Value Trading Fund OS LP | 37.8K | 1.00% | — | — | — | 37.8K | PN | Delaware | 2024-08-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-83 vs prev Q
New positions
2
Closed positions
77
Increased
6
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | 1.36M +1.0 (+0.0%) | 24.61M +7.4M (+42.9%) | 9.68% +0.000 pp | 0.83% +0.130 pp | USD10.17 +78.6% | 6 qtrs — |
| 2 | NANTAHALA CAPITAL MANAGEMENT, LLC | 1.24M +— (+0.0%) | 22.43M +6.7M (+42.9%) | 8.82% +0.000 pp | 0.74% +0.196 pp | USD8.69 +109.0% | 4 qtrs — |
| 3 | ORBIMED ADVISORS LLC | 1.19M -162.0K (-12.0%) | 21.56M +4.4M (+25.7%) | 8.48% -1.157 pp | 0.44% +0.038 pp | USD10.41 +74.4% | 6 qtrs — |
| 4 | AFFINITY ASSET ADVISORS, LLC | 1.05M +44.8K (+4.5%) | 19.09M +6.3M (+49.2%) | 7.51% +0.320 pp | 1.09% -0.027 pp | USD10.19 +78.2% | 8 qtrs — |
| 5 | CALIGAN PARTNERS LP | 881.5K +48.2K (+5.8%) | 16.01M +5.4M (+51.1%) | 6.30% +0.344 pp | 1.32% -0.069 pp | USD13.01 +39.6% | 2 qtrs — |
| 6 | VANGUARD GROUP INC | 804.1K +111.4K (+16.1%) | 14.60M +5.8M (+65.9%) | 5.74% +0.796 pp | 0.00% +0.000 pp | USD12.44 +46.0% | 7 qtrs — |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 663.0K +— (+0.0%) | 12.04M +3.6M (+42.9%) | 4.74% +0.000 pp | 0.12% +0.020 pp | USD9.50 +91.2% | 6 qtrs — |
| 8 | MILLENNIUM MANAGEMENT LLC | 660.0K +522.5K (+380.2%) | 11.99M +10.2M (+586.1%) | 4.71% +3.732 pp | 0.01% +0.004 pp | USD17.03 +6.6% | 2 qtrs — |
| 9 | POINT72 ASSET MANAGEMENT, L.P. | 627.5K -426.5K (-40.5%) | 11.40M -2.0M (-14.9%) | 4.48% -3.046 pp | 0.01% -0.010 pp | USD12.71 +42.9% | 2 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 621.4K +15.5K (+2.6%) | 11.28M +3.6M (+46.5%) | 4.44% -1.156 pp | 0.00% +0.000 pp | USD7.86 +131.0% | 7 qtrs — |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 550.0K +291.2K (+112.5%) | 9.99M +6.7M (+203.7%) | 3.93% +2.080 pp | 0.02% +0.010 pp | USD15.60 +16.4% | 2 qtrs — |
| 12 | SILVERARC CAPITAL MANAGEMENT, LLC | 524.4K -196.5K (-27.3%) | 9.52M +360.8K (+3.9%) | 3.75% -1.403 pp | 1.32% +0.087 pp | USD12.71 +42.9% | 2 qtrs — |
| 13 | MARSHALL WACE, LLP | 507.6K +451.5K (+806.2%) | 9.22M +8.5M (+1,194.8%) | 3.63% +3.225 pp | 0.01% +0.008 pp | USD17.56 +3.4% | 2 qtrs — |
| 14 | COMMODORE CAPITAL LP | 483.0K +— (+0.0%) | 8.77M +2.6M (+42.9%) | 3.45% +0.000 pp | 0.58% +0.284 pp | USD9.76 +86.1% | 7 qtrs — |
| 15 | TCG CROSSOVER MANAGEMENT, LLC | 483.0K +— (+0.0%) | 8.77M +2.6M (+42.9%) | 3.45% +0.000 pp | 0.29% -0.012 pp | USD9.50 +91.2% | 6 qtrs — |
| 16 | UBS GROUP AG | 477.8K +432.6K (+956.9%) | 8.68M +8.1M (+1,410.1%) | 3.41% +3.090 pp | 0.00% +0.001 pp | USD17.19 +5.6% | 9 qtrs — |
| 17 | JENNISON ASSOCIATES LLC | 475.6K +475.6K (+100.0%) | 8.64M +8.6M (+100.0%) | 3.40% +3.397 pp | 0.01% +0.005 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 18 | SOLEUS CAPITAL MANAGEMENT, L.P. | 442.0K +442.0K (+100.0%) | 8.03M +8.0M (+100.0%) | 3.16% +3.157 pp | 0.30% +0.296 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 19 | BALYASNY ASSET MANAGEMENT L.P. | 439.3K -378.1K (-46.3%) | 7.98M -2.4M (-23.2%) | 3.14% -2.701 pp | 0.01% -0.003 pp | USD12.71 +42.9% | 2 qtrs — |
| 20 | CITADEL ADVISORS LLC | 419.5K -62.2K (-12.9%) | 7.62M +1.5M (+24.4%) | 3.00% -0.444 pp | 0.00% +0.000 pp | USD12.71 +42.9% | 2 qtrs — |
| 21 | PATIENT SQUARE CAPITAL LP | 312.0K +212.0K (+212.0%) | 5.67M +4.4M (+345.7%) | 2.23% +1.514 pp | 1.21% +0.873 pp | USD16.41 +10.7% | 2 qtrs — |
| 22 | BLACKROCK, INC. | 289.6K +135.3K (+87.7%) | 5.26M +3.3M (+168.2%) | 2.07% +0.967 pp | 0.00% +0.000 pp | USD12.26 +48.1% | 6 qtrs — |
| 23 | BOXER CAPITAL MANAGEMENT, LLC | 275.0K +150.0K (+120.0%) | 4.99M +3.4M (+214.3%) | 1.96% +0.810 pp | 1.09% +0.587 pp | USD15.68 +15.8% | 2 qtrs — |
| 24 | MORGAN STANLEY | 264.9K +264.9K (+2,648,970.0%) | 4.81M +4.8M (+3,787,861.4%) | 1.89% +1.892 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 9 qtrs — |
| 25 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 263.6K +— (+0.0%) | 4.79M +1.4M (+42.9%) | 1.88% +0.000 pp | 2.78% -0.370 pp | USD9.21 +97.2% | 5 qtrs — |
| 26 | FMR LLC | 220.3K +220.3K (+100.0%) | 4.00M +4.0M (+100.0%) | 1.57% +1.574 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 27 | AMERIPRISE FINANCIAL INC | 218.0K +4.4K (+2.1%) | 3.96M +1.2M (+45.8%) | 1.56% +0.031 pp | 0.00% +0.000 pp | USD12.82 +41.7% | 2 qtrs — |
| 28 | JAIN GLOBAL LLC | 217.3K +217.3K (+100.0%) | 3.95M +3.9M (+100.0%) | 1.55% +1.552 pp | 0.02% +0.019 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 211.0K +163.6K (+345.2%) | 3.83M +3.2M (+536.0%) | 1.51% +1.169 pp | 0.00% +0.000 pp | USD16.94 +7.2% | 2 qtrs — |
| 30 | BOOTHBAY FUND MANAGEMENT, LLC | 202.1K -26.2K (-11.5%) | 3.67M +769.0K (+26.5%) | 1.44% -0.187 pp | 0.05% +0.013 pp | USD12.33 +47.3% | 6 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 197.7K +197.7K (+3,954,840.0%) | 3.59M +3.6M (+5,610,971.9%) | 1.41% +1.412 pp | 0.00% +0.002 pp | USD18.16 +0.0% | 8 qtrs — |
| 32 | SUMMITTX CAPITAL, L.P. | 195.9K +195.9K (+100.0%) | 3.56M +3.6M (+100.0%) | 1.40% +1.399 pp | 0.11% +0.107 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 33 | NAN FUNG TRINITY (HK) LTD | 189.0K +189.0K (+100.0%) | 3.43M +3.4M (+100.0%) | 1.35% +1.350 pp | 0.27% +0.272 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 34 | JANE STREET GROUP, LLC | 178.9K +178.9K (+100.0%) | 3.25M +3.2M (+100.0%) | 1.28% +1.278 pp | 0.00% +0.001 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 35 | GEODE CAPITAL MANAGEMENT, LLC | 166.2K +62.0K (+59.5%) | 3.02M +1.7M (+127.7%) | 1.19% +0.443 pp | 0.00% +0.000 pp | USD11.52 +57.6% | 6 qtrs — |
| 36 | SUPERSTRING CAPITAL MANAGEMENT LP | 153.3K -34.8K (-18.5%) | 2.78M +393.7K (+16.5%) | 1.10% -0.248 pp | 1.49% -0.865 pp | USD12.71 +42.9% | 2 qtrs — |
| 37 | CAPTION MANAGEMENT, LLC | 150.0K +150.0K (+100.0%) | 2.72M +2.7M (+100.0%) | 1.07% +1.071 pp | 0.02% +0.019 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 38 | DEUTSCHE BANK AG\ | 150.0K +150.0K (+100.0%) | 2.72M +2.7M (+100.0%) | 1.07% +1.071 pp | 0.00% +0.001 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 39 | TWO SIGMA INVESTMENTS, LP | 148.2K +99.0K (+201.0%) | 2.69M +2.1M (+330.1%) | 1.06% +0.707 pp | 0.00% +0.003 pp | USD15.68 +15.8% | 3 qtrs — |
| 40 | PERCEPTIVE ADVISORS LLC | 139.7K +— (+0.0%) | 2.54M +761.2K (+42.9%) | 1.00% +0.000 pp | 0.05% -0.006 pp | USD8.01 +126.7% | 4 qtrs — |
| 41 | STEMPOINT CAPITAL LP | 135.6K +135.6K (+100.0%) | 2.46M +2.5M (+100.0%) | 0.97% +0.968 pp | 0.42% +0.422 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 42 | MOODY ALDRICH PARTNERS LLC | 133.2K +133.2K (+100.0%) | 2.42M +2.4M (+100.0%) | 0.95% +0.952 pp | 0.45% +0.452 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 43 | — | 130.0K +130.0K (+100.0%) | 2.36M +2.4M (+100.0%) | 0.93% +0.929 pp | 1.00% +1.001 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 44 | GREAT POINT PARTNERS LLC | 124.7K +124.7K (+100.0%) | 2.26M +2.3M (+100.0%) | 0.89% +0.890 pp | 0.73% +0.734 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 45 | BARCLAYS PLC | 105.8K +96.5K (+1,032.2%) | 1.92M +1.8M (+1,517.7%) | 0.76% +0.689 pp | 0.00% +0.000 pp | USD17.68 +2.7% | 2 qtrs — |
| 46 | HIGHVISTA STRATEGIES LLC | 95.6K +67.9K (+244.3%) | 1.74M +1.4M (+391.9%) | 0.68% +0.485 pp | 0.45% +0.361 pp | USD16.58 +9.5% | 2 qtrs — |
| 47 | ABRDN PLC | 95.4K +22.6K (+31.1%) | 1.73M +807.6K (+87.3%) | 0.68% +0.162 pp | 0.00% +0.001 pp | USD14.00 +29.7% | 2 qtrs — |
| 48 | FRED ALGER MANAGEMENT, LLC | 80.1K +80.1K (+100.0%) | 1.45M +1.5M (+100.0%) | 0.57% +0.572 pp | 0.01% +0.006 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 49 | STATE STREET CORP | 79.3K +33.8K (+74.4%) | 1.44M +861.5K (+149.1%) | 0.57% +0.241 pp | 0.00% +0.000 pp | USD15.03 +20.8% | 2 qtrs — |
| 50 | SIO CAPITAL MANAGEMENT, LLC | 72.2K +— (+0.0%) | 1.31M +393.3K (+42.9%) | 0.52% +0.000 pp | 0.21% -0.026 pp | USD13.28 +36.7% | 8 qtrs — |
| 51 | GOLDMAN SACHS GROUP INC | 65.3K +65.3K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.47% +0.467 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 52 | QUBE RESEARCH & TECHNOLOGIES LTD | 64.5K +64.5K (+100.0%) | 1.17M +1.2M (+100.0%) | 0.46% +0.460 pp | 0.00% +0.001 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 53 | IKARIAN CAPITAL, LLC | 58.1K +58.1K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.42% +0.415 pp | 0.08% +0.082 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 54 | 683 CAPITAL MANAGEMENT, LLC | 56.9K +56.9K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.41% +0.406 pp | 0.04% +0.045 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 55 | QUADRATURE CAPITAL LTD | 53.0K -2.0K (-3.6%) | 963.3K +267.5K (+38.5%) | 0.38% -0.014 pp | 0.01% +0.002 pp | USD11.17 +62.6% | 3 qtrs — |
| 56 | WOODLINE PARTNERS LP | 52.0K +52.0K (+100.0%) | 945.1K +945.1K (+100.0%) | 0.37% +0.372 pp | 0.00% +0.004 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 57 | ATOM INVESTORS LP | 51.2K +51.2K (+100.0%) | 929.7K +929.7K (+100.0%) | 0.37% +0.366 pp | 0.07% +0.074 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 58 | TWO SIGMA ADVISERS, LP | 49.4K +49.4K (+100.0%) | 897.1K +897.1K (+100.0%) | 0.35% +0.353 pp | 0.00% +0.002 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 59 | JPMORGAN CHASE & CO | 44.4K +42.9K (+2,724.6%) | 806.9K +786.9K (+3,935.9%) | 0.32% +0.303 pp | 0.00% +0.000 pp | USD17.96 +1.1% | 9 qtrs — |
| 60 | WALLEYE CAPITAL LLC | 41.7K -3.1K (-6.8%) | 757.1K +188.5K (+33.1%) | 0.30% -0.022 pp | 0.00% +0.000 pp | USD10.27 +76.8% | 5 qtrs — |
| 61 | ARTIA GLOBAL PARTNERS LP | 41.6K +41.6K (+100.0%) | 754.9K +754.9K (+100.0%) | 0.30% +0.297 pp | 0.12% +0.120 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 62 | SQUAREPOINT OPS LLC | 40.9K +40.9K (+100.0%) | 741.9K +741.9K (+100.0%) | 0.29% +0.292 pp | 0.00% +0.001 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 63 | XTX TOPCO LTD | 40.5K +26.5K (+190.0%) | 734.7K +557.4K (+314.4%) | 0.29% +0.189 pp | 0.02% +0.010 pp | USD16.28 +11.5% | 2 qtrs — |
| 64 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 32.3K +32.3K (+100.0%) | 586.0K +586.0K (+100.0%) | 0.23% +0.231 pp | 0.00% +0.005 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 65 | NORTHERN TRUST CORP | 32.2K +13.6K (+73.4%) | 584.8K +348.7K (+147.7%) | 0.23% +0.097 pp | 0.00% +0.000 pp | USD11.97 +51.7% | 5 qtrs — |
| 66 | GLENMEDE TRUST CO NA | 20.5K +20.5K (+100.0%) | 371.4K +371.4K (+100.0%) | 0.15% +0.146 pp | 0.00% +0.002 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 67 | OMERS ADMINISTRATION CORP | 19.6K +19.6K (+100.0%) | 355.9K +355.9K (+100.0%) | 0.14% +0.140 pp | 0.00% +0.003 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 68 | RENAISSANCE TECHNOLOGIES LLC | 18.3K -80.4K (-81.5%) | 332.3K -922.1K (-73.5%) | 0.13% -0.574 pp | 0.00% -0.001 pp | USD12.71 +42.9% | 2 qtrs — |
| 69 | HUDSON BAY CAPITAL MANAGEMENT LP | 16.8K +16.8K (+100.0%) | 304.6K +304.6K (+100.0%) | 0.12% +0.120 pp | 0.00% +0.001 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 70 | ENVESTNET ASSET MANAGEMENT INC | 16.0K +16.0K (+100.0%) | 291.3K +291.3K (+100.0%) | 0.11% +0.115 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 71 | PERSISTENT ASSET PARTNERS LTD | 15.1K +15.1K (+100.0%) | 274.0K +274.0K (+100.0%) | 0.11% +0.108 pp | 0.12% +0.123 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 72 | JUMP FINANCIAL, LLC | 13.1K +13.1K (+100.0%) | 237.8K +237.8K (+100.0%) | 0.09% +0.094 pp | 0.00% +0.003 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 73 | BELVEDERE TRADING LLC | 10.1K +10.1K (+100.0%) | 183.4K +183.4K (+100.0%) | 0.07% +0.072 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 74 | TOWER RESEARCH CAPITAL LLC (TRC) | 8.7K +8.7K (+33,503.8%) | 158.7K +158.3K (+47,980.0%) | 0.06% +0.062 pp | 0.00% +0.004 pp | USD18.14 +0.1% | 2 qtrs — |
| 75 | US BANCORP \DE\ | 2.7K +2.7K (+100.0%) | 49.6K +49.6K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 76 | PFS PARTNERS, LLC | 2.0K +1.0K (+100.0%) | 36.3K +23.6K (+185.8%) | 0.01% +0.007 pp | 0.02% +0.011 pp | USD15.44 +17.6% | 2 qtrs — |
| 77 | ACADIAN ASSET MANAGEMENT LLC | 1.5K +1.5K (+100.0%) | 26.0K +26.0K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD18.16 +0.0% | 1 qtrs NEW |
| 78 | CITIGROUP INC | 1.1K +743.0 (+185.8%) | 20.8K +15.7K (+308.3%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD16.25 +11.8% | 2 qtrs — |
| 79 | GROUP ONE TRADING, L.P. | 1.00 -280.0 (-99.6%) | 18.00 -3.6K (-99.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD12.00 +51.3% | 9 qtrs — |
| 80 | ADVISOR GROUP HOLDINGS, INC. | 1.00 -1.0 (-50.0%) | 18.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.00 +39.7% | 9 qtrs — |
| 81 | ACTIVEST WEALTH MANAGEMENT | 1.00 +— (+0.0%) | 18.00 +5.0 (+38.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.00 +51.3% | 7 qtrs — |
| 82 | KEY FINANCIAL INC | 1.00 +— (+0.0%) | 18.00 +5.0 (+38.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.00 +51.3% | 7 qtrs — |
| 83 | PARALLEL ADVISORS, LLC | 1.00 +— (+0.0%) | 18.00 +5.0 (+38.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.00 +6.8% | 8 qtrs — |
| 84 | ADVISER INVESTMENTS LLC | — -86.5K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.618 pp | 0.00% -0.013 pp | USD— | 4 qtrs SOLD |
| 85 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | — -33.3K (-100.0%) | — -423.7K (-100.0%) | 0.00% -0.238 pp | 0.00% -0.027 pp | USD— | 2 qtrs SOLD |
| 86 | PRELUDE CAPITAL MANAGEMENT, LLC | — -24.6K (-100.0%) | — -313.0K (-100.0%) | 0.00% -0.176 pp | 0.00% -0.024 pp | USD— | 2 qtrs SOLD |
| 87 | ALLY BRIDGE GROUP (NY) LLC | — -178.1K (-100.0%) | — -2.3M (-100.0%) | 0.00% -1.272 pp | 0.00% -1.379 pp | USD— | 2 qtrs SOLD |
| 88 | DLD ASSET MANAGEMENT, LP | — -23.4K (-100.0%) | — -296.6K (-100.0%) | 0.00% -0.167 pp | 0.00% -0.016 pp | USD— | 2 qtrs SOLD |
| 89 | SIMPLEX TRADING, LLC | — -748.0 (-100.0%) | — -9.0K (-100.0%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 56 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.80% | 461.1K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.36% | 130.1K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.36% | 39.09M | 0.35% |
| 4 | iShares Micro-Cap ETF IWC | 0.18% | 2.69M | 0.60% |
| 5 | iShares Health Innovation Active ETF BMED | 0.14% | 15.0K | 0.77% |
| 6 | Pacer WealthShield ETF PWS | 0.07% | 18.1K | 0.60% |
| 7 | T. Rowe Price Innovation Leaders ETF TNXT | 0.05% | 8.6K | 0.49% |
| 8 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.05% | 315.9K | 0.96% |
| 9 | Fidelity Enhanced Small Cap ETF FESM | 0.04% | 2.20M | 0.28% |
| 10 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 365.4K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.26
Bearish
Ratio by volume
0.46
Bearish
Buys
9
Sells
34
Shares acquired
234.9K
Shares disposed
505.9K
Cash buys
—
Cash sales
25.00
Net activity
-270,987
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Sullivan Christopher Ryan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 18,606 | 9.88 | 183.8K | 168,094 | D | ↗ |
| 2026-05-06 | VARKI PAUL | Officer | S-Sale | D | Common Stock | 22,839 | 21.22 | 484.5K | 13,287 | D | ↗ |
| 2026-05-06 | Sullivan Christopher Ryan | Officer | S-Sale | D | Common Stock | 12,347 | 19.28 | 238.1K | 21,242 | D | ↗ |
| 2026-05-06 | Doyle Mittie | Officer | S-Sale | D | Common Stock | 10,058 | 22.88 | 230.1K | 3,622 | D | ↗ |
| 2026-05-06 | Chan Mitchell | Director | S-Sale | D | Common Stock | 3,167 | 22.88 | 72.5K | 3,166 | D | ↗ |
| 2026-05-05 | Doyle Mittie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 679 | 8.04 | 5.5K | 147,650 | D | ↗ |
| 2026-04-30 | Sullivan Christopher Ryan | Officer | S-Sale | D | Common Stock | 8,457 | 13.23 | 111.9K | 423 | D | ↗ |
| 2026-04-29 | Sullivan Christopher Ryan | Officer | S-Sale | D | Common Stock | 8,458 | 13.09 | 110.7K | 8,880 | D | ↗ |
| 2026-04-06 | Doyle Mittie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,970 | 12.65 | 50.2K | 210,530 | D | ↗ |
| 2026-04-02 | Sullivan Christopher Ryan | Officer | S-Sale | D | Common Stock | 1,780 | 17.57 | 31.3K | 17,338 | D | ↗ |
| 2026-04-01 | Sullivan Christopher Ryan | Officer | S-Sale | D | Common Stock | 7,479 | 16.83 | 125.8K | 25,318 | D | ↗ |
| 2026-04-01 | Doyle Mittie | Officer | S-Sale | D | Common Stock | 679 | 16.00 | 10.9K | 3,622 | D | ↗ |
| 2026-03-31 | Lind Kevin Robert | Director | A-Award | A | Stock Option (Right to Buy) | 1,370 | 14.93 | 20.5K | 1,370 | D | ↗ |
| 2026-03-31 | Jain Rita | Director | A-Award | A | Stock Option (Right to Buy) | 1,339 | 14.93 | 20.0K | 1,339 | D | ↗ |
| 2026-03-28 | Truex Samantha | Director | M-Exempt | A | Common Stock | 3,166 | 0.00 | — | 6,333 | D | ↗ |
| 2026-03-28 | Sullivan Christopher Ryan | Officer | M-Exempt | D | Restricted Stock Units | 24,200 | 0.00 | — | 24,200 | D | ↗ |
| 2026-03-28 | NEIL GARRY ARTHUR | Director / Officer | M-Exempt | D | Restricted Stock Units | 64,866 | 0.00 | — | 64,867 | D | ↗ |
| 2026-03-28 | KAPLAN GILLA | Director | M-Exempt | D | Restricted Stock Units | 3,166 | 0.00 | — | 3,167 | D | ↗ |
| 2026-03-28 | KANTOFF AARON | Director | M-Exempt | A | Common Stock | 3,166 | 0.00 | — | 6,333 | D | ↗ |
| 2026-03-28 | Goldman Jonathan | Director | M-Exempt | A | Common Stock | 3,166 | 0.00 | — | 3,166 | D | ↗ |
| 2026-03-28 | Chan Mitchell | Director | M-Exempt | D | Restricted Stock Units | 3,166 | 0.00 | — | 3,167 | D | ↗ |
| 2026-03-16 | Doyle Mittie | Officer | M-Exempt | D | Stock Option (Right to Buy) | 19,500 | 12.65 | 246.7K | 214,500 | D | ↗ |
| 2026-02-26 | VARKI PAUL | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 17.64 | 1.41M | 80,000 | D | ↗ |
| 2026-02-26 | Sullivan Christopher Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 17.64 | 1.85M | 105,000 | D | ↗ |
| 2026-02-26 | Riley Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 17.64 | 1.68M | 95,000 | D | ↗ |
| 2026-02-26 | NEIL GARRY ARTHUR | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 286,000 | 17.64 | 5.05M | 286,000 | D | ↗ |
| 2026-02-26 | Doyle Mittie | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 17.64 | 1.85M | 105,000 | D | ↗ |
| 2026-02-26 | Boyd Taylor | Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 17.64 | 1.68M | 95,000 | D | ↗ |
| 2025-12-31 | Lind Kevin Robert | Director | A-Award | A | Stock Option (Right to Buy) | 848 | 18.16 | 15.4K | 848 | D | ↗ |
| 2025-12-31 | Jain Rita | Director | A-Award | A | Stock Option (Right to Buy) | 1,043 | 18.16 | 18.9K | 1,043 | D | ↗ |
| 2025-12-10 | VARKI PAUL | Officer | F-InKind | D | Common Stock | 1,016 | 4.10 | 4.2K | 3,634 | D | ↗ |
| 2025-12-10 | Sullivan Christopher Ryan | Officer | F-InKind | D | Common Stock | 155 | 4.10 | 635.50 | 17,338 | D | ↗ |
| 2025-12-10 | Riley Jennifer | Officer | F-InKind | D | Common Stock | 637 | 4.10 | 2.6K | 2,655 | D | ↗ |
| 2025-12-10 | Doyle Mittie | Officer | F-InKind | D | Common Stock | 1,013 | 4.10 | 4.2K | 3,622 | D | ↗ |
| 2025-11-14 | Goldman Jonathan | Director | S-Sale | D | Common Stock | 8,200 | 14.35 | 117.6K | 0 | D | ↗ |
| 2025-10-01 | Lind Kevin Robert | Director | A-Award | A | Stock Option (Right to Buy) | 40,200 | 12.96 | 521.0K | 40,200 | D | ↗ |
| 2025-10-01 | Boyd Taylor | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 12.96 | 3.56M | 275,000 | D | ↗ |
| 2025-09-30 | Jain Rita | Director | A-Award | A | Stock Option (Right to Buy) | 1,572 | 12.71 | 20.0K | 1,572 | D | ↗ |
| 2025-06-17 | Truex Samantha | Director | A-Award | A | Stock Option (Right to Buy) | 20,100 | 4.47 | 89.8K | 20,100 | D | ↗ |
| 2025-06-17 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 20,100 | 4.47 | 89.8K | 20,100 | D | ↗ |
| 2025-06-17 | KANTOFF AARON | Director | A-Award | A | Stock Option (Right to Buy) | 20,100 | 4.47 | 89.8K | 20,100 | D | ↗ |
| 2025-06-17 | Jain Rita | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-17 | Heffernan Michael Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 29,500 | 4.47 | 131.9K | 29,500 | D | ↗ |
| 2025-06-17 | Goldman Jonathan | Director | A-Award | A | Stock Option (Right to Buy) | 20,100 | 4.47 | 89.8K | 20,100 | D | ↗ |
| 2025-06-17 | Chan Mitchell | Director | A-Award | A | Stock Option (Right to Buy) | 20,100 | 4.47 | 89.8K | 20,100 | D | ↗ |
| 2025-06-17 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 20,100 | 4.47 | 89.8K | 20,100 | D | ↗ |
| 2025-03-28 | Truex Samantha | Director | M-Exempt | A | Common Stock | 3,167 | 0.00 | — | 3,167 | D | ↗ |
| 2025-03-28 | Sullivan Christopher Ryan | Officer | F-InKind | D | Common Stock | 7,285 | 8.46 | 61.6K | 16,921 | D | ↗ |
| 2025-03-28 | NEIL GARRY ARTHUR | Officer | M-Exempt | A | Common Stock | 64,867 | 0.00 | — | 64,927 | D | ↗ |
| 2025-03-28 | KAPLAN GILLA | Director | M-Exempt | D | Restricted Stock Units | 3,167 | 0.00 | — | 6,333 | D | ↗ |
| 2025-03-28 | KANTOFF AARON | Director | M-Exempt | A | Common Stock | 3,167 | 0.00 | — | 3,167 | D | ↗ |
| 2025-03-28 | Goldman Jonathan | Director | M-Exempt | A | Common Stock | 3,167 | 0.00 | — | 3,167 | D | ↗ |
| 2025-03-28 | Chan Mitchell | Director | M-Exempt | A | Common Stock | 3,167 | 0.00 | — | 3,167 | D | ↗ |
| 2025-03-28 | Almenoff June Sherie | Director | M-Exempt | A | Common Stock | 3,167 | 0.00 | — | 3,167 | D | ↗ |
| 2025-03-25 | Heffernan Michael Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.54 | 427.0K | 50,000 | D | ↗ |
| 2025-01-28 | VARKI PAUL | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 8.04 | 804.0K | 100,000 | D | ↗ |
| 2025-01-28 | Sullivan Christopher Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 163,000 | 8.04 | 1.31M | 163,000 | D | ↗ |
| 2025-01-28 | NEIL GARRY ARTHUR | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 411,000 | 8.04 | 3.30M | 411,000 | D | ↗ |
| 2025-01-28 | Doyle Mittie | Officer | A-Award | A | Stock Option (Right to Buy) | 155,000 | 8.04 | 1.25M | 155,000 | D | ↗ |
| 2025-01-01 | Riley Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 7.43 | 1.11M | 150,000 | D | ↗ |
| 2024-11-13 | Almenoff June Sherie | Director | P-Purchase | A | Common Stock | 500 | 13.00 | 6.5K | 1,000 | I | ↗ |
| 2024-11-12 | Almenoff June Sherie | Director | P-Purchase | A | Common Stock | 500 | 12.50 | 6.2K | 500 | I | ↗ |
| 2024-08-13 | Truex Samantha | Director | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2024-08-13 | Sullivan Christopher Ryan | Officer | A-Award | A | Restricted Stock Units | 72,600 | 0.00 | — | 72,600 | — | ↗ |
| 2024-08-13 | NEIL GARRY ARTHUR | Director / Officer | A-Award | A | Restricted Stock Units | 194,600 | 0.00 | — | 194,600 | — | ↗ |
| 2024-08-13 | KAPLAN GILLA | Director | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2024-08-13 | KANTOFF AARON | Director | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2024-08-13 | Goldman Jonathan | Director | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2024-08-13 | Chan Mitchell | Director | A-Award | A | Restricted Stock Units | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2024-08-13 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 24,600 | 9.88 | 243.0K | 24,600 | — | ↗ |
| 2024-07-15 | Doyle Mittie | Officer | A-Award | A | Stock Option (Right to Buy) | 234,000 | 12.65 | 2.96M | 234,000 | — | ↗ |
| 2024-06-24 | VARKI PAUL | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 13.43 | 2.01M | 150,000 | — | ↗ |
| 2024-03-28 | Truex Samantha | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-28 | KANTOFF AARON | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-27 | Goldman Jonathan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-20 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 3,334 | 0.04 | 143.36 | 3,334 | — | ↗ |
| 2023-12-20 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 3,334 | 0.04 | 143.36 | 3,334 | — | ↗ |
| 2023-12-20 | Chan Mitchell | Director | A-Award | A | Stock Option (Right to Buy) | 3,334 | 0.04 | 143.36 | 3,334 | — | ↗ |
| 2023-12-20 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 3,334 | 0.04 | 143.36 | 3,334 | — | ↗ |
| 2023-06-30 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 28,308 | 0.36 | 10.1K | 28,308 | — | ↗ |
| 2023-06-30 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 4,575 | 0.36 | 1.6K | 4,575 | — | ↗ |
| 2023-06-27 | ARMISTICE CAPITAL, LLC | 10% Owner | S-Sale | D | Common Stock | 937,404 | 0.52 | 486.9K | 731,458 | — | ↗ |
| 2023-06-26 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | D | Common Stock | 182,300 | 0.62 | 113.0K | 0 | — | ↗ |
| 2023-06-26 | ARMISTICE CAPITAL, LLC | 10% Owner | S-Sale | D | Common Stock | 2,746,138 | 0.61 | 1.68M | 1,668,862 | — | ↗ |
| 2023-06-20 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 2,000 | 4.14 | 8.3K | 1,425,700 | — | ↗ |
| 2023-06-16 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 3,000 | 3.90 | 11.7K | 1,423,700 | — | ↗ |
| 2023-06-15 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 3,160 | 3.68 | 11.6K | 1,420,700 | — | ↗ |
| 2023-06-14 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 6,000 | 3.48 | 20.9K | 1,417,540 | — | ↗ |
| 2023-06-13 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 8,750 | 3.82 | 33.4K | 1,411,540 | — | ↗ |
| 2023-06-12 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 2,149 | 4.34 | 9.3K | 1,402,790 | — | ↗ |
| 2023-06-09 | Sullivan Christopher Ryan | Officer | P-Purchase | A | Common Stock | 511 | 3.42 | 1.7K | 1,262 | — | ↗ |
| 2023-06-09 | NEIL GARRY ARTHUR | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 3.42 | 13.7K | 13,220 | — | ↗ |
| 2023-06-09 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 5,044 | 4.14 | 20.9K | 1,400,641 | — | ↗ |
| 2023-06-08 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 6,398 | 3.93 | 25.1K | 1,395,597 | — | ↗ |
| 2023-06-07 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 2,984 | 3.49 | 10.4K | 1,389,199 | — | ↗ |
| 2023-05-31 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 844 | 2.87 | 2.4K | 1,386,215 | — | ↗ |
| 2023-05-30 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 671 | 2.87 | 1.9K | 1,385,371 | — | ↗ |
| 2023-05-25 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 2,000 | 2.77 | 5.5K | 1,384,700 | — | ↗ |
| 2023-05-24 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 5,519 | 2.96 | 16.3K | 1,382,700 | — | ↗ |
| 2023-05-22 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 7,000 | 3.34 | 23.4K | 1,373,700 | — | ↗ |
| 2023-05-19 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 6,500 | 3.52 | 22.9K | 1,366,700 | — | ↗ |
| 2023-05-18 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 13,121 | 3.29 | 43.2K | 1,360,200 | — | ↗ |
| 2023-05-16 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 379 | 2.75 | 1.0K | 1,347,079 | — | ↗ |
| 2023-05-15 | Sullivan Christopher Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.75 | 110.0K | 40,000 | — | ↗ |
| 2023-05-15 | NEIL GARRY ARTHUR | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.75 | 275.0K | 100,000 | — | ↗ |
| 2023-05-15 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 1,715 | 2.55 | 4.4K | 1,346,700 | — | ↗ |
| 2023-05-12 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common stock | 2,285 | 2.45 | 5.6K | 1,344,985 | — | ↗ |
| 2023-05-08 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 5,000 | 2.62 | 13.1K | 1,342,700 | — | ↗ |
| 2023-05-05 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 5,000 | 2.88 | 14.4K | 1,337,700 | — | ↗ |
| 2023-05-04 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 15,000 | 2.79 | 41.9K | 1,332,700 | — | ↗ |
| 2023-04-27 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 1,504 | 2.96 | 4.5K | 1,317,700 | — | ↗ |
| 2023-04-26 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 425 | 2.97 | 1.3K | 1,316,196 | — | ↗ |
| 2023-04-25 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 5,571 | 3.00 | 16.7K | 1,315,771 | — | ↗ |
| 2023-04-24 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 12,500 | 3.06 | 38.3K | 1,310,200 | — | ↗ |
| 2023-04-20 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 5,000 | 3.08 | 15.4K | 1,297,700 | — | ↗ |
| 2023-04-18 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 2.94 | 29.4K | 1,292,700 | — | ↗ |
| 2023-04-17 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 15,000 | 2.96 | 44.4K | 1,282,700 | — | ↗ |
| 2023-04-11 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 25,000 | 2.84 | 71.1K | 1,267,700 | — | ↗ |
| 2023-04-10 | Caissa Capital Management ltd. | 10% Owner | P-Purchase | A | Common Stock | 31,329 | 2.28 | 71.4K | 1,242,700 | — | ↗ |
| 2023-03-31 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 7,222 | 1.75 | 12.6K | 7,222 | — | ↗ |
| 2023-03-31 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 1,167 | 1.75 | 2.0K | 1,167 | — | ↗ |
| 2023-02-13 | Sullivan Christopher Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.98 | 119.2K | 40,000 | — | ↗ |
| 2023-02-13 | NEIL GARRY ARTHUR | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.98 | 298.0K | 100,000 | — | ↗ |
| 2023-02-07 | ARMISTICE CAPITAL, LLC | 10% Owner | P-Purchase | A | Warrant | 450,000 | 5.00 | 2.25M | 450,000 | — | ↗ |
| 2023-02-03 | ARMISTICE CAPITAL, LLC | 10% Owner | L-Small | A | Common Stock | 334 | 3.95 | 1.3K | 3,965,000 | — | ↗ |
| 2022-12-30 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 2,536 | 0.00 | — | 2,536 | — | ↗ |
| 2022-12-30 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 410 | 0.00 | — | 410 | — | ↗ |
| 2022-12-09 | NEIL GARRY ARTHUR | Officer | P-Purchase | A | Common Stock | 2,083 | 4.42 | 9.2K | 9,220 | — | ↗ |
| 2022-10-05 | Sullivan Christopher Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-10-05 | NEIL GARRY ARTHUR | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-09-30 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 3,747 | 0.00 | — | 3,747 | — | ↗ |
| 2022-09-30 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 3,080 | 0.00 | — | 3,080 | — | ↗ |
| 2022-09-30 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 605 | 0.00 | — | 605 | — | ↗ |
| 2022-06-30 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 26,837 | 0.50 | 13.4K | 26,837 | — | ↗ |
| 2022-06-30 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 44,115 | 0.50 | 22.1K | 44,115 | — | ↗ |
| 2022-06-30 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 4,338 | 0.50 | 2.2K | 4,338 | — | ↗ |
| 2022-06-14 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.44 | 17.6K | 40,000 | — | ↗ |
| 2022-06-14 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-14 | Chan Mitchell | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.44 | 17.6K | 40,000 | — | ↗ |
| 2022-06-14 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-03-31 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 18,468 | 0.00 | — | 18,468 | — | ↗ |
| 2022-03-31 | Miller Joseph M | Director | A-Award | A | Stock Option (Right to Buy) | 20,239 | 0.00 | — | 20,239 | — | ↗ |
| 2022-03-31 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 30,359 | 0.00 | — | 30,359 | — | ↗ |
| 2022-03-31 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 2,985 | 0.72 | 2.2K | 2,985 | — | ↗ |
| 2022-03-10 | Boyd Steven | Director | P-Purchase | A | Common Stock | 100,000 | 0.65 | 64.9K | 47,576,000 | — | ↗ |
| 2022-03-08 | Sullivan Christopher Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 0.00 | — | 400,000 | — | ↗ |
| 2022-03-08 | NEIL GARRY ARTHUR | Officer | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 0.70 | 700.0K | 1,000,000 | — | ↗ |
| 2022-03-03 | Boyd Steven | Director | P-Purchase | A | Common Stock | 50,000 | 0.71 | 35.7K | 46,890,000 | — | ↗ |
| 2022-02-25 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 40,000 | 0.79 | 31.7K | 46,840,000 | — | ↗ |
| 2022-02-24 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.80 | 80.1K | 46,800,000 | — | ↗ |
| 2022-02-22 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 83,000 | 0.77 | 64.1K | 46,700,000 | — | ↗ |
| 2022-02-18 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 55,000 | 0.82 | 45.2K | 46,617,000 | — | ↗ |
| 2022-02-17 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 150,000 | 0.82 | 122.3K | 46,562,000 | — | ↗ |
| 2022-01-18 | ARMISTICE CAPITAL, LLC | Director | P-Purchase | A | Common Stock | 12,000 | 0.85 | 10.2K | 46,412,000 | — | ↗ |
| 2022-01-14 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 85,000 | 0.93 | 79.0K | 46,100,000 | — | ↗ |
| 2022-01-13 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 312,700 | 1.00 | 314.0K | 46,015,000 | — | ↗ |
| 2022-01-12 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 57,300 | 1.04 | 59.8K | 45,702,300 | — | ↗ |
| 2022-01-11 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 16,003 | 0.96 | 15.3K | 45,645,000 | — | ↗ |
| 2022-01-10 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 491,097 | 0.99 | 484.6K | 45,628,997 | — | ↗ |
| 2022-01-07 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 137,900 | 1.04 | 143.0K | 45,137,900 | — | ↗ |
| 2022-01-04 | Smolinski Stephen | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.70 | 680.0K | 400,000 | — | ↗ |
| 2022-01-03 | Smolinski Stephen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 7,943 | 1.70 | 13.5K | 7,943 | — | ↗ |
| 2021-12-31 | Miller Joseph M | Director | A-Award | A | Stock Option (Right to Buy) | 8,920 | 1.70 | 15.2K | 8,920 | — | ↗ |
| 2021-12-31 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 12,767 | 1.70 | 21.7K | 12,767 | — | ↗ |
| 2021-12-31 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 737 | 1.70 | 1.3K | 737 | — | ↗ |
| 2021-12-10 | Wilkins H Jeffrey | Officer | P-Purchase | A | Common Stock | 6,371 | 1.57 | 10.0K | 33,373 | — | ↗ |
| 2021-12-10 | Sullivan Christopher Ryan | Officer | P-Purchase | A | Common Stock | 955 | 1.57 | 1.5K | 9,004 | — | ↗ |
| 2021-12-10 | NEIL GARRY ARTHUR | Officer | P-Purchase | A | Common Stock | 4,267 | 1.57 | 6.7K | 85,639 | — | ↗ |
| 2021-12-10 | Harrell James Archie Jr | Officer | P-Purchase | A | Common Stock | 1,093 | 1.57 | 1.7K | 36,766 | — | ↗ |
| 2021-12-10 | Greenway Schond L. | Officer | P-Purchase | A | Common Stock | 2,231 | 1.57 | 3.5K | 3,883 | — | ↗ |
| 2021-12-01 | Gutry Phil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-01 | Chan Mitchell | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 1.87 | 149.6K | 80,000 | — | ↗ |
| 2021-11-10 | Bruhn Suzanne Louise | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-10 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 2.28 | 182.4K | 80,000 | — | ↗ |
| 2021-10-15 | Maher Illya Keith | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-01 | COLA MICHAEL F | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 78,116 | 2.25 | 175.8K | 78,116 | — | ↗ |
| 2021-09-30 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 5,985 | 2.18 | 13.0K | 5,985 | — | ↗ |
| 2021-09-30 | Miller Joseph M | Director | A-Award | A | Stock Option (Right to Buy) | 6,939 | 2.18 | 15.1K | 6,939 | — | ↗ |
| 2021-09-30 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 9,541 | 2.18 | 20.8K | 9,541 | — | ↗ |
| 2021-09-30 | Gutry Phil | Director | A-Award | A | Stock Option (Right to Buy) | 4,718 | 2.18 | 10.3K | 4,718 | — | ↗ |
| 2021-09-30 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (Right to Buy) | 5,204 | 2.18 | 11.3K | 5,204 | — | ↗ |
| 2021-09-17 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 5,454,545 | 2.20 | 12.00M | 45,000,000 | — | ↗ |
| 2021-09-16 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 150,000 | 2.28 | 342.0K | 39,545,455 | — | ↗ |
| 2021-09-15 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 95,455 | 2.26 | 215.9K | 39,395,455 | — | ↗ |
| 2021-08-06 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 2.83 | 70.6K | 39,250,000 | — | ↗ |
| 2021-08-05 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 2.77 | 69.3K | 39,225,000 | — | ↗ |
| 2021-08-04 | ARMISTICE CAPITAL, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 2.69 | 268.6K | 39,200,000 | — | ↗ |
| 2021-07-01 | COLA MICHAEL F | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 51,740 | 3.39 | 175.4K | 51,740 | — | ↗ |
| 2021-06-30 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 3,985 | 3.27 | 13.0K | 3,985 | — | ↗ |
| 2021-06-30 | Miller Joseph M | Director | A-Award | A | Stock Option (Right to Buy) | 4,620 | 3.27 | 15.1K | 4,620 | — | ↗ |
| 2021-06-30 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 6,353 | 3.27 | 20.8K | 6,353 | — | ↗ |
| 2021-06-30 | Gutry Phil | Director | A-Award | A | Stock Option (Right to Buy) | 3,142 | 3.27 | 10.3K | 3,142 | — | ↗ |
| 2021-06-30 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (Right to Buy) | 3,465 | 3.27 | 11.3K | 3,465 | — | ↗ |
| 2021-06-15 | Persson Magnus | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.56 | 142.4K | 40,000 | — | ↗ |
| 2021-06-15 | Miller Joseph M | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.56 | 142.4K | 40,000 | — | ↗ |
| 2021-06-15 | KAPLAN GILLA | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.56 | 142.4K | 40,000 | — | ↗ |
| 2021-06-15 | Gutry Phil | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.56 | 142.4K | 40,000 | — | ↗ |
| 2021-06-15 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.56 | 142.4K | 40,000 | — | ↗ |
| 2021-06-15 | BARER SOL J | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.56 | 142.4K | 40,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-31.7K
Shares Outstanding
11.29M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Garry Neil, M.D. Chief Executive Officer, President and principal executive officer | 590.0K | — | — | 2.73M | 475.0K | 10.3K | 3.81M | 71.76% | ↗ |
| 2 | 2025 | Taylor Boyd Chief Business Officer | 116.3K | — | — | 3.05M | 52.1K | 1.9K | 3.22M | 94.71% | ↗ |
| 3 | 2025 | Mittie Doyle, M.D., FACR Chief Medical Officer | 512.5K | — | — | 1.03M | 229.6K | 8.0K | 1.78M | 57.87% | ↗ |
| 4 | 2024 | Garry Neil, M.D. Chief Executive Officer, President and principal executive officer | 532.5K | — | 1.92M | 4.26M | 501.8K | — | 7.21M | 85.66% | ↗ |
| 5 | 2024 | Mittle Doyle, M.D, FACR Chief Medical Officer | 231.1K | — | — | 2.59M | 216.0K | — | 3.03M | 85.26% | ↗ |
| 6 | 2024 | Mittie Doyle, M.D., FACR Chief Medical Officer | 231.1K | — | — | 2.59M | 216.0K | — | 3.03M | 85.26% | ↗ |
| 7 | 2024 | Christopher Sullivan Chief Financial Officer and principal financial officer | 400.0K | — | 712.3K | 1.59M | 229.4K | — | 2.93M | 78.52% | ↗ |
| 8 | 2023 | Garry Neil, M.D. Chief Executive Officer, President and principal executive officer | 475.0K | — | — | 434.1K | 166.3K | — | 1.08M | 40.37% | ↗ |
| 9 | 2023 | Garry Neil, M.D. Chief Executive Officer, President, Chairman of the Board and principal executive officer | 475.0K | — | — | 434.1K | 166.3K | — | 1.08M | 40.37% | ↗ |
| 10 | 2023 | Christopher Sullivan Chief Financial Officer and principal financial officer | 350.0K | — | — | 173.6K | 84.0K | — | 607.6K | 28.58% | ↗ |
| 11 | 2022 | Garry Neil, M.D. Chief Executive Officer, President, Chairman of the Board and principal executive officer | 468.9K | — | — | 730.9K | 133.0K | — | 1.33M | 54.84% | ↗ |
| 12 | 2022 | Stephen Smolinski Former Chief Commercial Officer | 74.2K | — | — | 489.9K | 11.6K | 415.1K | 990.9K | 49.45% | ↗ |
| 13 | 2022 | Michael Cola Former Chief Executive Officer and former principal executive officer | 62.5K | — | — | — | 17.3K | 865.7K | 945.4K | 0.00% | ↗ |
| 14 | 2022 | Christopher Sullivan Chief Financial Officer and principal financial officer | 344.1K | — | — | 301.6K | 72.8K | 50.0K | 768.5K | 39.24% | ↗ |
| 15 | 2021 | Michael Cola Former Chief Executive Officer and former principal executive officer | 35.6K | — | — | 2.33M | 325.5K | — | 2.69M | 86.60% | ↗ |
| 16 | 2021 | Schond Greenway Former Chief Financial Officer and former principal financial officer | 293.3K | — | — | 1.24M | 141.7K | — | 1.68M | 74.06% | ↗ |
| 17 | 2021 | H. Jeffrey Wilkins, M.D. Former Chief Medical Officer | 425.0K | — | — | 659.4K | 165.6K | — | 1.25M | 52.75% | ↗ |
| 18 | 2021 | Garry Neil, M.D. Chief Executive Officer, President, Chairman of the Board and principal executive officer | 423.0K | — | — | 571.5K | 239.6K | — | 1.23M | 46.31% | ↗ |
| 19 | 2021 | Christopher Sullivan Chief Financial Officer and principal financial officer | 300.0K | — | — | 241.8K | 85.9K | — | 627.6K | 38.52% | ↗ |
| 20 | 2020 | Michael Cola Former Chief Executive Officer and former principal executive officer | 79.2K | — | — | 3.36M | 378.0K | — | 3.82M | 88.03% | ↗ |
| 21 | 2020 | Michael Cola Chief Executive Officer and principal executive officer | 79.2K | 378.0K | — | — | — | — | 3.82M | 0.00% | ↗ |
| 22 | 2020 | Garry Neil, M.D. Chief Scientific Officer | 372.9K | 296.0K | — | — | — | — | 2.69M | 0.00% | ↗ |
| 23 | 2020 | H. Jeffrey Wilkins, M.D. Chief Medical Officer | 335.5K | 178.0K | — | 974.2K | — | — | 1.49M | 65.48% | ↗ |
| 24 | 2020 | H. Jeffrey Wilkins, M.D. Former Chief Medical Officer | 335.5K | — | — | 974.2K | 178.0K | — | 1.49M | 65.48% | ↗ |
| 25 | 2020 | Joseph Miller Former Chief Financial Officer, former principal financial officer, and former principal executive officer | 116.7K | — | — | — | — | 115.5K | 232.3K | 0.00% | ↗ |
| 26 | 2019 | Simon Pedder, Ph.D. Former Executive Chairman of the Board | 247.9K | 157.5K | 1.25M | 1.86M | — | 270.3K | 3.78M | 82.11% | ↗ |
| 27 | 2019 | Pericles Calias, Ph.D. Former Chief Scientific Officer | 324.2K | 140.0K | 224.1K | 657.1K | — | — | 1.35M | 65.50% | ↗ |
| 28 | 2019 | Joseph Miller Former Chief Financial Officer, former Principal Financial Officer, and former Principal Executive Officer | 356.0K | 222.0K | — | 592.6K | — | — | 1.17M | 50.62% | ↗ |
| 29 | 2019 | Joseph Miller Former Chief Financial Officer, former principal financial officer, and former principal executive officer | 356.0K | 222.0K | — | — | — | — | 1.17M | 0.00% | ↗ |
| 30 | 2019 | Peter Greenleaf Former Chief Executive Officer and former Principal Executive Officer | 175.8K | — | — | — | — | 559.5K | 735.2K | 0.00% | ↗ |
| 31 | 2018 | Peter Greenleaf Former Chief Executive Officer and former Principal Executive Officer | 456.0K | 360.0K | 1.70M | 2.57M | — | 10.0K | 5.09M | 83.77% | ↗ |
| 32 | 2018 | Peter Greenleaf Former Chief Executive Officer | 456.0K | 360.0K | 1.70M | 2.57M | — | 10.0K | 5.09M | 83.77% | ↗ |
| 33 | 2018 | Mariam E. Morris Former Chief Financial Officer | 164.8K | — | — | 186.9K | — | 335.8K | 687.5K | 27.18% | ↗ |
| 34 | 2018 | Joseph Miller Former Chief Financial Officer, former Principal Financial Officer, and former Principal Executive Officer | 153.6K | 61.4K | 202.5K | 255.5K | — | — | 673.0K | 68.06% | ↗ |
| 35 | 2018 | Joseph M. Miller Chief Financial Officer, Principal Executive Officer and Principal Financial Officer | 153.6K | 61.4K | 202.5K | 255.5K | — | — | 673.0K | 68.06% | ↗ |
| 36 | 2018 | James A. Harrell, Jr. Executive Vice President, Marketing and External Communications | 201.5K | 124.0K | — | 296.0K | — | — | 621.5K | 47.63% | ↗ |
| 37 | 2018 | Pericles Calias, Ph.D. Former Chief Scientific Officer | 119.2K | 47.9K | — | 184.3K | — | — | 351.3K | 52.45% | ↗ |
| 38 | 2018 | Robert C. Moscato, Jr Former President, Chief Operating Officer and Director | 70.7K | — | — | — | — | 200.0K | 270.7K | 0.00% | ↗ |
| 39 | 2018 | Simon Pedder, Ph.D. Former Executive Chairman of the Board | — | — | — | — | — | 27.6K | 27.6K | 0.00% | ↗ |
| 40 | 2017 | Uli Hacksell, Ph.D. Former President and Chief Executive Officer | 439.6K | — | — | 67.2K | — | 46.4K | 553.1K | 12.15% | ↗ |
| 41 | 2017 | Mariam E. Morris Former Chief Financial Officer | 295.2K | 78.8K | 16.8K | — | — | 6.7K | 397.5K | 4.23% | ↗ |
| 42 | 2017 | Ronald Marcus, M.D. Former Chief Medical Officer | 354.1K | — | — | — | — | 19.1K | 373.3K | 0.00% | ↗ |
| 43 | 2017 | John Kaiser Former Chief Business Officer and interim Chief Executive Officer | 321.9K | — | — | 27.1K | — | 6.7K | 355.6K | 7.61% | ↗ |
| 44 | 2017 | Mariam E. Morris Chief Financial Officer | 295.2K | — | — | 16.8K | — | 6.7K | 318.7K | 5.27% | ↗ |
| 45 | 2017 | Peter Greenleaf Former Chief Executive Officer | — | — | — | — | — | 29.1K | 29.1K | 0.00% | ↗ |
| 46 | 2017 | Robert C. Moscato, Jr Former President, Chief Operating Officer and Director | 25.0K | — | — | — | — | — | 25.0K | 0.00% | ↗ |
| 47 | 2016 | Uli Hacksell, Ph.D. President and Chief Executive Officer | 500.0K | — | — | 1.19M | — | 60.0K | 1.75M | 67.93% | ↗ |
| 48 | 2016 | Uli Hacksell, Ph.D. Former President and Chief Executive Officer | 500.0K | — | — | 1.19M | — | 60.0K | 1.75M | 67.93% | ↗ |
| 49 | 2016 | Ronald Marcus, M.D. Chief Medical Officer | 356.2K | — | — | 200.9K | — | 24.0K | 581.1K | 34.58% | ↗ |
| 50 | 2016 | Ronald Marcus, M.D. Former Chief Medical Officer | 356.2K | — | — | 200.9K | — | 24.0K | 581.1K | 34.58% | ↗ |
| 51 | 2016 | John Kaiser Former Chief Business Officer and interim Chief Executive Officer | 297.0K | — | — | 153.4K | — | — | 450.4K | 34.06% | ↗ |
| 52 | 2016 | John Kaiser Chief Business Officer | 297.0K | — | — | 153.4K | — | — | 450.4K | 34.06% | ↗ |
| 53 | 2016 | Mariam E. Morris Chief Financial Officer | 295.2K | — | — | 112.2K | — | 24.7K | 432.1K | 25.97% | ↗ |
| 54 | 2015 | Blake M. Paterson, M.D. Former President and Chief Executive Officer | 395.2K | 207.5K | — | 468.0K | — | 19.2K | 1.09M | 42.94% | ↗ |
| 55 | 2015 | Ronald Marcus, M.D. Chief Medical Officer | 213.4K | 63.5K | — | 208.6K | — | 19.0K | 504.4K | 41.35% | ↗ |
| 56 | 2015 | John Kaiser Chief Business Officer | 292.0K | 89.1K | — | 117.0K | — | — | 498.1K | 23.49% | ↗ |
| 57 | 2014 | Blake M. Paterson, M.D. Former President and Chief Executive Officer | 390.0K | 199.1K | — | 96.8K | — | — | 685.9K | 14.11% | ↗ |
| 58 | 2014 | John Kaiser Chief Business Officer | 290.7K | 116.5K | — | 45.7K | — | — | 452.9K | 10.10% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Garry A. Neil | President, Chief Executive Officer & Director | 1M | — |
| Mittie Doyle FACR | Chief Medical Officer | 750.1K | — |
| Christopher Ryan Sullivan | Chief Financial Officer & Head of Investor relations | 629.4K | male |
| Taylor Boyd | Chief Business Officer | 519.0K | male |
| Dino C. Miano | Senior Vice President of CMC & Technical Operations | — | — |
| Colleen Matkowski | Senior Vice President of Global Regulatory Affairs & Quality Assurance | — | female |
| Jennifer Riley | Chief Strategy Officer | — | female |
| Barbara S. Slusher | Founder and Member of Scientific Advisory Board | — | — |
| Paul C. Varki | Chief Legal Officer | — | male |
| Solomon H. Snyder | Founder and Chairman of Scientific Advisory Board | — | — |
| Ashley Ivanowicz | Senior Vice President of Human Resources | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
